VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Anheuser-Busch InBev SA/NV vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Anheuser-Busch InBev SA/NV
ABI · Euronext Brussels
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Anheuser-Busch InBev SA/NV's moat claims, evidence, and risks.
View ABI analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: Anheuser-Busch InBev SA/NV leads (75 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: Anheuser-Busch InBev SA/NV has 6 segments (28.6% in Middle Americas); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Duopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Anheuser-Busch InBev SA/NV has 5 moat types across 3 domains; AstraZeneca PLC has 4 across 3.
Primary market context
Anheuser-Busch InBev SA/NV
Middle Americas
Beer and malt-based beverages (plus growing no-alcohol and Beyond Beer)
Mexico, Central America, and Caribbean (AB InBev reporting segment)
Retailers and on-premise outlets
Brewer / brand owner + route-to-market operator
28.6%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
Anheuser-Busch InBev SA/NV strengths
AstraZeneca PLC strengths
Segment mix
Anheuser-Busch InBev SA/NV segments
Full profile >North America
Oligopoly
Middle Americas
Duopoly
South America
Oligopoly
EMEA
Oligopoly
Asia Pacific
Competitive
Global Export & Holding Companies
Competitive
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.